Progressive myoclonus epilepsy associated with SACS gene mutations
- PMID: 27433545
- PMCID: PMC4936476
- DOI: 10.1212/NXG.0000000000000083
Progressive myoclonus epilepsy associated with SACS gene mutations
Abstract
Pathogenic variants in the SACS gene (OMIM #604490) cause autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS). ARSACS is a neurodegenerative early-onset progressive disorder, originally described in French Canadians, but later observed elsewhere.(1) Whole-exome sequencing of a large group of patients with unclassified progressive myoclonus epilepsies (PMEs) identified 2 patients bearing SACS gene mutations.(2) We detail the PME clinical features associated with SACS mutations and suggest the inclusion of the SACS gene in diagnostic screening of PMEs.
Figures

References
-
- Engert JC, Berube P, Mercier J, et al. . ARSACS, a spastic ataxia common in northeastern Quebec, is caused by mutations in a new gene encoding an 11.5-kb. Nat Genet 2000;24:120–125. - PubMed
-
- Baets J, Deconinck T, Smets K, et al. . Mutations in SACS cause atypical and late-onset forms of ARSACS. Neurology 2010;75:1181–1188. - PubMed
-
- Stevens J, Murphy SM, Davagnanam I, et al. . The ARSACS phenotype can include supranuclear gaze palsy and skin lipofuscin deposits. J Neurol Neurosurg Psychiatry 2012;83:1–2. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials